Identification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension
Aparna, P.; Rao, S.V.; Thomas, K.M.; Mukkanti, K.; Badarinadh Gupta, P.; Rangarao, K.; Narayan, G.K.; Sandip, T.; Upendra, K.
Die Pharmazie 65(5): 331-335
2010
ISSN/ISBN: 0031-7144 PMID: 20503923 Document Number: 643030
An unknown impurity (degradation product) present at a level below 0.1% in the initial sample was increased to 0.25% in 50 degrees C 3 M stability samples of lamivudine, zidovudine and nevirapine tablets for oral suspension, as detected by gradient reverse phase HPLC. This degradation product was isolated using reverse phase preparative HPLC. Based on the spectral data, the structure of this degradation product is characterized as 1-[5-hydroxymethyl-4-(5-methyl-2,3-dihydro-[1,2,3]triazole-1-yl)-tetrahydrofuran-2-yl]-5-methyl-1 H-pyrimidine-2,4-(1H,3H)dione. Structural elucidation of this degradation product was carried out using MS, 1H NMR, 13C NMR, DEPT and IR spectral data. The formation of this impurity and its mechanism are discussed.
Document emailed within 1 workday
Related Documents
Zijenah, L.S.; Kadzirange, G.; Rusakaniko, S.; Kufa, T.; Gonah, N.; Tobaiwa, O.; Gwanzura, C.; Matsikire, E.; Katzenstein, D.A. 2006: A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe Central African Journal of Medicine 52(1-2): 1-8Fortes Déguénonvo, L.; Diop, S.A.; Leye, M.M.M.; Seydi, M.; Dieng, A.B.; Bentaleb, H.; Diouf, A.; Lakhe, N.A.; Ka, D.; Cisse, V.M.P.; Dia Badiane, N.M.; Manga, M.N.; Ndour, C.T.; Soumaré, M.; Diop, B.M.; Sow, P.S. 2013: Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar Bulletin de la Societe de Pathologie Exotique 106(4): 244-247
Katlama, C.; Ingrand, D.; Loveday, C.; Clumeck, N.; Mallolas, J.; Staszewski, S.; Johnson, M.; Hill, A.M.; Pearce, G.; McDade, H. 1996: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. a randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group JAMA 276(2): 118-125
Goodgame, J.C.; Pottage, J.C.; Jablonowski, H.; Hardy, W.D.; Stein, A.; Fischl, M.; Morrow, P.; Feinberg, J.; Brothers, C.H.; Vafidis, I.; Nacci, P.; Yeo, J.; Pedneault, L. 2000: Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team Antiviral Therapy 5(3): 215-225
Vanprapar, N.; Cressey, T.R.; Chokephaibulkit, K.; Muresan, P.; Plipat, N.; Sirisanthana, V.; Prasitsuebsai, W.; Hongsiriwan, S.; Chotpitayasunondh, T.; Eksaengsri, A.; Toye, M.; Smith, M.E.; McIntosh, K.; Capparelli, E.; Yogev, R. 2010: A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand Pediatric Infectious Disease Journal 29(10): 940-944
Van Leeuwen, R.; Lange, J.M.; Nijhuis, M.; Schuurman, R.; Reiss, P.; Danner, S.A.; Boucher, C.A. 1997: Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine Antiviral Therapy 2(2): 79-90
Manosuthi, W.; Kiertiburanakul, S.; Chaovavanich, A.; Sungkanuparph, S. 2007: Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients Journal of the Medical Association of Thailand 90(2): 244-250
Staszewski, S.; Keiser, P.; Montaner, J.; Raffi, F.; Gathe, J.; Brotas, V.; Hicks, C.; Hammer, S.M.; Cooper, D.; Johnson, M.; Tortell, S.; Cutrell, A.; Thorborn, D.; Isaacs, R.; Hetherington, S.; Steel, H.; Spreen, W. 2001: Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial JAMA 285(9): 1155-1163
Gartland, M. 2001: AVANTi 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients Antiviral Therapy 6(2): 127-134
Moolasart, P.; Likanonsakul, S. 2002: The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children Southeast Asian Journal of Tropical Medicine and Public Health 33(2): 280-287
Monif, T.; Tippabhotla, S.K.; Garg, M.; Singla, A.K.; Vijan, T. 2006: Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition International Journal of Clinical Pharmacology and Therapeutics 44(6): 276-283
Jayapalu, K.; Malipeddi, H. 2017: Stability Indicative Hplc Determination of Related Substances and Identification of Potential Degradants using Lc-Ms in Triple Combination Antiretroviral Tablets Acta Poloniae Pharmaceutica 74(1): 81-92
Kiertiburanakul, S.; Khongnorasat, S.; Rattanasiri, S.; Sungkanuparph, S. 2007: Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients Journal of the Medical Association of Thailand 90(2): 237-243
Pensi, T. 2007: Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report Indian pediatrics 44(7): 519-521
Idigbe, E.O.; Adewole, T.A.; Eisen, G.; Kanki, P.; Odunukwe, N.N.; Onwujekwe, D.I.; Audu, R.A.; Araoyinbo, I.D.; Onyewuche, J.I.; Salu, O.B.; Adedoyin, J.A.; Musa, A.Z. 2005: Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program Journal of Acquired Immune Deficiency Syndromes 40(1): 65-69
Getahun, A.; Tansuphasawadikul, S.; Desakorn, V.; Dhitavat, J.; Pitisuttithum, P. 2006: Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection Journal of the Medical Association of Thailand 89(9): 1472-1478
de Vincenzi, I.; Farley, T.; Gaillard, P.; Meda, N.; Rollins, N.; Luchters, S.; Nduati, R.; Newell, M-Louise.; Read, J.; Dioulasso, B.; Faso, B.; Meda, N.; Fao, P.; Ky-Zerbo, O.; Gouem, C.; Somda, P.; Hien, Hé.; Ouedraogo, P.Elysée.; Kania, D.; Sanou, A.; Kossiwavi, I.Ayassou.; Sanogo, B.; Ouedraogo, M.; Siribie, I.; Valéa, D.; Ouedraogo, S.; Somé, R.; Rouet, Fçois.; Rollins, N.; McFetridge, L.; Naidu, K.; Luchters, S.; Reyners, M.; Irungu, E.; Katingima, C.; Mwaura, M.; Ouattara, G.; Mandaliya, K.; Wambua, S.; Thiongo, M.; Nduati, R.; Kose, J 2011: Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial Lancet. Infectious Diseases 11(3): 171-180
Desakorn, V.; Karmacharya, B.Man.; Thanachartwet, V.; Kyaw, N.Lin.; Tansuphaswadikul, S.; Sahassananda, D.; Dhitavat, J.; Maek-a-nantawat, W.; Pitisuttithum, P. 2011: Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up Southeast Asian Journal of Tropical Medicine and Public Health 42(6): 1414-1422
Staszewski, S.; Katlama, C.; Harrer, T.; Massip, P.; Yeni, P.; Cutrell, A.; Tortell, S.M.; Harrigan, R.P.; Steel, H.; Lanier, R.E.; Pearce, G. 1998: A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects Aids 12(16): F197-F202
Anekthananon, T.; Ratanasuwan, W.; Techasathit, W.; Sonjai, A.; Suwanagool, S. 2004: Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study Journal of the Medical Association of Thailand 87(7): 760-767